Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well-tolerated, oral treatments of cancer and other serious illnesses.
Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.
Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, pancreatic cancer, breast cancer, and prevention of acute kidney injury in hospitalized patients with pneumonia.
Dec. 2024
Cantex Pharmaceuticals announced that the FDA granted Orphan Drug Designation to Cantex’s azeliragon for the treatment of brain metastasis from breast cancer.
Oct. 2024
Drug Delivery Leader’s “Sit and Deliver” Video Interview: Cantex’s CEO, Dr. Stephen Marcus, discusses the company’s development of azeliragon as an oral, small molecule for multiple cancers and cancer-related indications.
August 2024
Doctor Podcasts EPISODE 61: (Watch video)
FDA approval of a new drug is a complex, rigorous, lengthy, expensive but necessary process. Find out how it’s done from Stephen G. Marcus, M.D., CEO of Cantex Pharmaceuticals. Dr. Marcus is running clinical trials of potential blockbuster drug Azeliragon.